ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Educational Symposium

Caring for the Patient with AKI in Cirrhosis: New Tools and Opportunities

November 03, 2023 | 12:45 PM - 01:45 PM

Location: Grand Ballroom Salon L, Level 5, Philadelphia Marriott Downtown

Session Description

AKI is common in patients with decompensated cirrhosis and entails a poor prognosis. If left untreated, the rapidly progressive renal failure associated with type 1 hepatorenal syndrome (HRS), now known as HRS-AKI, has a median survival time of approximately 2 weeks and greater than 80% mortality within 3 months. Volume overload and concomitant illness continue to make the diagnosis of HRS-AKI challenging. Moreover, the cornerstones of HRS-AKI therapy, volume expansion and vasoconstrictors, present serious risks in this patient population.

With the recent US Food and Drug Administration approval of the vasopressin analog, terlipressin, for the treatment of HRS-AKI, this symposium covers risk factors and diagnostic algorithms to identify HRS-AKI; risks and benefits of volume expansion and vasoconstrictor therapeutic options; and emerging innovations in the diagnosis, monitoring, and care of patients with HRS-AKI.

Support is provided by an educational grant from Mallinckrodt Pharmaceuticals.

Learning Objective(s)

  • Describe the current diagnostic approach in patients with AKI and cirrhosis
  • Discuss emerging approaches to diagnose, monitor, and treat HRS-AKI
  • Examine the roles of volume expansion and vasoconstrictor therapy in HRS-AKI

Learning Pathway(s)

  • AKI and Critical Care